Cannabis compounds block the liver enzymes that process most prescription drugs
Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions
Bottom Line
Both THC and CBD significantly inhibit multiple liver enzymes (CYP450s) responsible for metabolizing roughly 60% of all prescription medications, meaning cannabis can increase blood levels of drugs you are already taking — sometimes dangerously.
Why It Matters
With millions of people using cannabis alongside prescription medications — including virtually all medical cannabis patients — the clinical implications are enormous. Cannabis does not just affect you; it affects how your body processes every other drug you take.
The Backstory
Most people who use cannabis also take other drugs. Not illicit drugs — prescription medications. SSRIs for depression. Benzodiazepines for anxiety. Blood pressure medications. Blood thinners. Pain medications. Anticonvulsants. Immunosuppressants. The average medical cannabis patient takes multiple prescription drugs.
In 2021, Shamema Nasrin and colleagues at Washington State University published two companion papers that revealed just how broadly cannabis compounds interfere with the liver enzymes that process these medications. The scope of the interference was larger, more persistent, and more clinically significant than most doctors — let alone patients — realized.
How Your Liver Processes Drugs
Your liver contains a family of enzymes called cytochrome P450 (CYP450) that metabolize — break down and deactivate — most drugs that enter your body. Different enzymes in this family handle different drugs. When one drug inhibits a CYP enzyme, it slows the metabolism of every other drug that enzyme processes. The other drugs linger longer in the bloodstream, at higher concentrations. Their effective dose increases without anyone prescribing a higher dose.
This is the mechanism behind most drug-drug interactions in medicine. It is not exotic pharmacology — it is how grapefruit juice increases the potency of certain medications (grapefruit inhibits CYP3A4). Cannabis does the same thing, but across a broader range of enzymes.
What Nasrin Found
~60%
of all prescription medications are metabolized by the CYP enzymes that THC and CBD inhibit. This is not a marginal finding. It means that for the majority of prescription drugs, cannabis has the potential to alter how your body processes them. The clinical significance varies — some interactions are trivial, others are potentially dangerous — but the breadth of the potential interaction is striking.
For context, the FDA's drug interaction warning for grapefruit juice — one of the most well-known food-drug interactions — involves primarily one enzyme (CYP3A4). Cannabis inhibits at least seven.
Nasrin et al. (2021)
The Highest-Risk Interactions
Not all drug interactions are clinically significant. The concern is greatest for medications with a narrow therapeutic index — drugs where the difference between an effective dose and a toxic dose is small.
The Metabolite Discovery
The finding that sets Nasrin's work apart from earlier drug interaction studies is the metabolite data. Previous research focused on THC and CBD as parent compounds. Nasrin showed that 11-OH-THC (the active metabolite that makes edibles feel different) and THC-COOH-glucuronide (the metabolite detected in standard drug tests) are also significant CYP inhibitors.
What You Should Do
The practical guidance is straightforward:
- Tell your doctor if you use cannabis. This is the single most important action. Many patients don't disclose because of stigma, but your doctor cannot manage drug interactions they don't know about.
- Tell your pharmacist too. Pharmacists screen for drug interactions as part of their standard workflow, but they can only include cannabis if they know about it.
- Don't adjust medications on your own. If you suspect an interaction, consult your prescriber before changing anything. Stopping a medication abruptly can be more dangerous than the interaction itself.
- Know your high-risk medications. If you take warfarin, immunosuppressants, opioids, or medications with narrow therapeutic windows, disclosure is not optional — it is a safety requirement.
- CBD products carry the same risk. Many consumers assume that CBD, being non-psychoactive, is pharmacologically inert. Nasrin's data shows CBD is a more potent CYP3A4 inhibitor than THC. This is especially relevant for the millions of people taking OTC CBD supplements alongside prescription medications.
Cite this study
Nasrin, Shamema; Watson, Christy J W; Perez-Paramo, Yadira X; Lazarus, Philip. (2021). Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions. Drug Metabolism and Disposition. https://doi.org/10.1124/dmd.121.000442